Payment overview · 2025
General Payments
$22,688.68
156 reported records · 20 companies
Healthcare provider profile · identity verified
Marloe Prince, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · KINGWOOD, TX · NPI 1740696343
Verified facts
What the public records show
CMS Open Payments records show Marloe Prince, M.D. received $22,688.68 in general payments during 2025 across 156 reported records.
ABIOMED accounted for 45.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $10,356.12 | 45.6% | 25 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $4,606.25 | 20.3% | 15 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $3,863.09 | 17.0% | 30 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,178.01 | 5.2% | 17 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $738.77 | 3.3% | 11 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $585.39 | 2.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $443.84 | 2.0% | 21 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $243.15 | 1.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $218.64 | 1.0% | 11 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $115.61 | 0.5% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $71.26 | 0.3% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $53.60 | 0.2% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $50.72 | 0.2% | 2 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $41.62 | 0.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.68 | 0.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.55 | 0.1% | 1 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $19.83 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.61 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.58 | 0.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $15.36 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $9,960.00 | 3 |
| Food and Beverage | $6,409.20 | 137 |
| Travel and Lodging | $3,819.48 | 13 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,500.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $4,606.25 | 15 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $3,105.81 | 11 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $622.04 | 10 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $585.39 | 3 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $585.39 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $532.27 | 6 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $444.21 | 4 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $420.97 | 16 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $336.31 | 3 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $193.74 | 5 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $192.81 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $154.43 | 8 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $115.61 | 2 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $100.82 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $71.26 | 8 | 2025 |
Source payment records
|
|||||
| Spotlight Normalized: spotlight |
Device | ABIOMED | $64.54 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.21 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.21 | 3 | 2025 |
Source payment records
|
|||||
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $58.40 | 2 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $53.63 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $53.60 | 3 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $42.82 | 3 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $41.62 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $28.55 | 2 | 2025 |
Source payment records
|
|||||
| General - Structural Heart Normalized: general structural heart |
Device | Boston Scientific Corporation | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $25.75 | 2 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| VersaCross Large Access Solution Normalized: versacross large access solution |
Device | Boston Scientific Corporation | $15.22 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 20 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 87 | 30 |
| Atorvastatin Calcium | Atorvastatin Calcium | 77 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 57 | 26 |
| Losartan Potassium | Losartan Potassium | 57 | 27 |
| Furosemide | Furosemide | 53 | 22 |
| Xarelto | Rivaroxaban | 49 | 19 |
| Eliquis | Apixaban | 42 | 20 |
| Carvedilol | Carvedilol | 41 | 18 |
| Prasugrel Hcl | Prasugrel Hcl | 40 | 20 |
| Entresto | Sacubitril/Valsartan | 39 | 12 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Metolazone | Metolazone | 28 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 14 |
| Chlorthalidone | Chlorthalidone | 26 | 15 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Lisinopril | Lisinopril | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22,688.68 · 156 records | ABIOMED | ABRE, ALPHAVAC, ANGIOVAC, AURYON LASER SYSTEM 100-120 VAC, AVEIR, CAMZYOS, CAPVAXIVE, CARDIOMEMS, COBENFY, COREVALVE EVOLUT R, ENDOCROSS Device, FARAPULSE, General - EP, General - Structural Heart, JOT DX, Kerendia, LIMFLOW SYSTEM, LifeVest, NUVISION ICE CATHETER, Ozempic, Paradise Ultrasound Renal Denervation System, REPATHA, Rybelsus, SYMPHONY CATHETER, SYMPLICITY G3, Spotlight, TREO ABDOMINAL STENT-GRAFT SYSTEM, Torus Stent Graft System, VERQUVO, Varithena Administration Pack, VersaCross Large Access Solution, WAINUA, WATCHMAN, WATCHMAN Access System, WATCHMAN FLX, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error